Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.59 |
| ▸ | PDE4A | P27815 | 10/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193968 | 0.85 | PDE4B (0.71) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL537296 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL537141 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869360 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL537524 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15869365 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15862397 | 0.83 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15252347 | 0.81 | TP53 (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL12488742 | 0.80 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL3113890 | 0.80 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | disclosed |
| EP-2683376-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-11-28 | — | — | EP | disclosed |
| EP-3320902-A1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-16 | — | — | EP | disclosed |